Indication
Advanced/Metastatic Head and Neck
1 clinical trial
4 products
Clinical trial
An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2021-12-30
Product
AtezolizumabProduct
VinorelbineProduct
Simlukafusp alfaProduct
Gemcitabine